The QQQQ has started creeping higher over the last few minutes. Looks like somebody's trying to get a head start on the quarter-end mark-ups.
Potential swing trades:
See one of the recent 'Chart Reading' posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
Gapping down on disppointing earnings/guidance: ATEA -28%, NMGC -14%, GNSS -9% (guidanice only; down in sympathy: TRID -2%), ERS -7.4%, MHK -5.1% (guidance only), HOM -3.3%, RUTH -2.1% (guidance only)... Other News: SRA -6.6% (stock offering), DSCO -6.4% (Phase 2 data), CNTY -5%, VOD -2.8%, BHP -2.1%, ERICY -2.1%, AVII -2%, TIVO -1.9% (Soleil comments on trial), BIIB -1.5% (cautious comments by Morgan Stanley cited), NHP -1.1% (prices offering)... Under $3: WSTM -26% (reports Q3, mulls strategic alternatives), HIV -7% (profit taking after recent run).
Gapping Up
MERX +17% (reports FebQ; guides above consensus; tgt raised to $15 at Credit Suisse), VICL +15% (vird flu clinical data; also Needham initiates with $8 tgt), DEIX +9.4% (reports Q4; see Briefing profile on Jan 20), EMIS +8% (clinical results), HANS +7.5% (Stifel says BUD and HANS may be consider partnership), EPCT +19% (Phase III Ceplene study results), TDSC +8%, AOB +7.1% (reports Q4), ZOLT +3.3% (announces grant from Hungarian govt), GROW +3.2%, MEDX +2.4% (starts registrational trial for Ipilimumab), LVLT +2.3% (bounces after 8% drop yesterday), NVAX +2.3% (holders convert notes to shares)... Mad Money mentions: HEES +4.6%, MOV +3.3%, RACK +2.6%, AKAM +2.2%, BRCD +1.9%... Under $3: BDCO +26% (reports Q4).
Disclaimer & How I use this list
